Shares of AgeX Therapeutics (NYSE:AGE) were up 5.3% on Wednesday . The company traded as high as $2.80 and last traded at $2.77, approximately 121,599 shares were traded during trading. An increase of 48% from the average daily volume of 82,319 shares. The stock had previously closed at $2.63.
The business has a 50-day moving average of $2.68 and a two-hundred day moving average of $3.54. The company has a debt-to-equity ratio of 0.03, a quick ratio of 2.54 and a current ratio of 2.54.
A number of institutional investors have recently made changes to their positions in AGE. Deutsche Bank AG purchased a new stake in shares of AgeX Therapeutics during the fourth quarter valued at about $37,000. Iowa State Bank bought a new position in shares of AgeX Therapeutics during the 2nd quarter worth approximately $40,000. Beirne Wealth Consulting Services LLC bought a new position in shares of AgeX Therapeutics during the 2nd quarter worth approximately $44,000. Susquehanna International Group LLP purchased a new stake in AgeX Therapeutics during the second quarter valued at approximately $80,000. Finally, Jane Street Group LLC purchased a new stake in AgeX Therapeutics during the second quarter valued at approximately $99,000. Institutional investors and hedge funds own 16.88% of the company’s stock.
About AgeX Therapeutics (NYSE:AGE)
AgeX Therapeutics, Inc, a biotechnology company, focuses on the development and commercialization of therapeutics for age-related degenerative diseases in the United Stated. The company is developing AGEX-BAT1 and AGEX-VASC1, which are cell-based approaches in the preclinical stage of development to correct metabolic imbalances in aging; and to restore vascular support in ischemic tissues.
Recommended Story: How to Invest in the Dividend Aristocrat Index
Receive News & Ratings for AgeX Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AgeX Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.